A randomised controlled equivalence trial to determine the effectiveness and cost–utility of manual chest physiotherapy techniques in the management of exacerbations of chronic obstructive pulmonary disease (MATREX)

J Cross,1* F Elender,1 G Barton,2 A Clark,2 L Shepstone,2 A Blyth,1 M Bachmann2 and I Harvey,2 on behalf of the MATREX Research Group

1School of Allied Health Professions, University of East Anglia, Norwich, UK
2School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, UK

*Corresponding author

Executive summary

Health Technology Assessment 2010; Vol. 14: No. 23
DOI: 10.3310/hta14230
Executive summary: MCP techniques in the management of exacerbations of COPD (MATREX)

Executive summary

Background

Manual chest physiotherapy (MCP) techniques, involving chest percussion, vibration and assisted coughing, have long been used in the treatment of respiratory conditions. However, strong evidence for the benefit of this intervention is lacking. Specifically with respect to chronic obstructive pulmonary disease (COPD), a review of the research literature indicates a clear state of clinical equipoise. Traditionally, patients hospitalised with an exacerbation of COPD have been given MCP to assist with sputum clearance. However, uncertainty as to whether it confers either short- or long-term benefits has led to wide variation in practice, with individual clinical preference tending to dictate whether or not a patient receives treatment.

Current clinical guidelines on the management of COPD are unable to provide evidence statements on physiotherapy interventions on account of inherent methodological limitations in existing research. The aim of this study was to address this situation by providing robust evidence on the effectiveness of MCP for this clinical population.

Objectives

To estimate the effect, if any, of MCP administered to patients hospitalised with COPD exacerbation on both disease-specific and generic health-related quality of life. To compare the health service costs for those who either receive or do not receive MCP while in hospital.

Design, setting and interventions

Using a pragmatic, randomised controlled trial design powered for equivalence we compared patients who either received or did not receive MCP while in hospital, in terms of disease-specific quality of life and health-care resource use, in the medium term (6 months), on an intention-to-treat (ITT) basis. The study employed active cycle of breathing techniques (ACBT) in both trial arms. Patients allocated to the intervention arm were guided to perform ACBT while the physiotherapist delivered MCP. For patients allocated to the control arm, the physiotherapist provided instruction on the elements of ACBT and advice on suitable positions to assist with sputum clearance.

Participants

Five hundred and twenty-six participants aged 34–91 years, recruited from four secondary care hospitals between November 2005 and April 2008, were randomised; of these, 372 participants provided evaluable data for the primary study outcome. All persons hospitalised with COPD exacerbation and evidence of sputum production on examination were eligible for the trial providing there were no contraindications to performing MCP.

Main outcome measure

The primary study outcome was COPD-specific quality of life, measured using the St George’s Respiratory Questionnaire (SGRQ). An effect size of 0.3 standard deviations in the SGRQ was specified in advance as the threshold for superiority.

The European Quality of Life-5 Dimensions (EQ-5D) questionnaire was employed as an additional generic health-related quality of life measure and used to calculate the quality-adjusted life-year (QALY) gain associated with MCP, compared with no MCP (incremental effect). Physiological outcome measures included the Breathlessness Cough and Sputum Scale (BCSS), the Medical Research Council-Dyspnoea (MRC-D) scale, sputum volume produced during hospitalisation, oxygen saturation at baseline and change in oxygen saturation associated with MCP. In addition, the Six-minute Walk Test (6MWT) was performed on a subsample of participants at one hospital site.

To estimate the incremental cost of MCP to the health service, physiotherapy input (including MCP), hospital admissions, outpatient visits and rehabilitation levels over the 6-month trial period were monitored for each patient. Appropriate unit
costs were assigned to each of these resources. The incremental cost and incremental effect of MCP was subsequently used to estimate the cost-effectiveness of MCP. Per-protocol (PP) analyses were performed for primary and secondary effectiveness end points and for QALYs.

Results

Health-related outcomes

Equivalence was demonstrated with respect to the primary outcome at the primary end point. The ITT analyses indicated no significant difference at 6 months in total SGRQ score [adjusted effect size (no MCP – MCP) 0.03 (95% confidence interval, CI –0.14 to 0.19)], SGRQ symptom score [adjusted effect size 0.04 (95% CI –0.15 to 0.23)], SGRQ activity score [adjusted effect size –0.02 (95% CI –0.20 to 0.16)] or SGRQ impact score [adjusted effect size 0.02 (95% CI –0.15 to 0.18)]. The imputed ITT and PP results were similar. No significant differences were observed in any of the outcome measures or subgroup analyses.

Cost-effectiveness

Compared with no MCP, employing MCP was associated with a slight loss in quality of life (0.001 QALY loss) but lower health service costs (cost saving of £410.79). Based on these estimates, at a cost-effectiveness threshold of $\lambda = \£20,000$ per QALY, MCP would be estimated to constitute a cost-effective use of resources (net benefit = £376.14), on the assumption that resources could be spent elsewhere in a more efficient manner. There was, however, a high level of uncertainty associated with these results (47.6% chance of making the wrong decision by choosing MCP when $\lambda = \£20,000$ per QALY) and one could not rule out the possibility that lower health service costs had been due to other factors. Moreover, though the results of the complete case analysis were in line with the base case, it should be noted that less than 50% of respondents provided complete EQ-5D data.

Conclusions

In terms of longer-term quality of life, the use of MCP does not appear to affect outcome in patients hospitalised for COPD exacerbation. Although the cost-effectiveness analysis suggested that MCP was cost-effective, much uncertainty was associated with this finding.

Implications for health care

1. This study addressed the limitations of previous research by standardising the delivery of MCP and obtaining a sample of sufficient size to derive statistically robust results for a patient-orientated, clinically meaningful outcome.
2. This study found no gain in longer-term quality of life when MCP was included in the physiotherapeutic management of acute exacerbation of COPD. However, the findings of this study do not mean that MCP is of no therapeutic value to patients with COPD in specific circumstances.
3. In terms of cost-effectiveness, MCP was associated with lower overall health service costs, with the cost of providing therapy offset by savings associated with fewer hospital admissions among patients assigned to receive MCP. However, interpretation of this apparent saving should be examined in the light of the primary outcome, which demonstrated no evidence of efficacy above normal care. As MCP was not found to be effective, it is difficult to justify providing this therapy on the basis of the results of the cost-effectiveness analysis alone. Furthermore, there is no guarantee that that any cost savings identified would be realised by employing MCP in routine care.
4. This study developed an MCP treatment that reflects professional consensus on best practice. With respect to the essential elements of MCP, it clarifies potential areas of ambiguity and provides a set of clear parameters within which treatment can be given. The high level of adherence to the MCP treatment protocol used in this trial suggests that it would be acceptable among the profession as a generic tool for delivering therapy.

Recommendations for research

With respect to the primary aim of the MATREX trial, further research is not required to demonstrate equivalence between receiving and not receiving MCP. Further research on the level of cost-effectiveness is unlikely to yield gains, as the benefits of both MCP and no MCP were similar and thus the consequences of making the wrong decision are small. As such, the cost of further research is likely to outweigh the value of information that would be gained. However, the findings of this study do not mean that MCP is of no therapeutic value to patients with COPD in specific circumstances.
The research questions arising from this study are listed below in order of priority:

- Is MCP effective for patients with COPD producing high volumes of sputum?
- Can the risk of oxygen desaturation during MCP be predicted?
- Is ACBT effective in treating COPD exacerbation?
- What are the trends over time in admission and survival rates for COPD?
- How can health-related resource use be more accurately identified?

**Trial registration**

This trial is registered as ISRCTN13825248.

**Publication**

How to obtain copies of this and other HTA programme reports
An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).

Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue.

How to order:
– fax (with credit card details)
– post (with credit card details or cheque)
– phone during office hours (credit card only).

Additionally the HTA website allows you to either print out your order or download a blank order form.

Contact details are as follows:
Synergie UK (HTA Department) Email: orders@hta.ac.uk
Digital House, The Loddon Centre Tel: 0845 812 4000 – ask for ‘HTA Payment Services’
Wade Road (out-of-hours answer-phone service)
Basingstoke Hants RG24 8QW Fax: 0845 812 4001 – put ‘HTA Order’ on the fax header

Payment methods
Paying by cheque
If you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.

Paying by credit card
You can order using your credit card by phone, fax or post.

Subscriptions
NHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40–50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.

How do I get a copy of HTA on DVD?
Please use the form on the HTA website (www.hsta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.

The website also provides information about the HTA programme and lists the membership of the various committees.
The Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the ‘National Knowledge Service’.

The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects.

First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, from the public and consumer groups and from professional bodies such as royal colleges and NHS trusts. These suggestions are carefully prioritised by panels of independent experts (including NHS service users). The HTA programme then commissions the research by competitive tender.

Second, the HTA programme provides grants for clinical trials for researchers who identify research questions. These are assessed for importance to patients and the NHS, and scientific rigour.

Third, through its Technology Assessment Report (TAR) call-off contract, the HTA programme commissions bespoke reports, principally for NICE, but also for other policy-makers. TARs bring together evidence on the value of specific technologies.

Some HTA research projects, including TARs, may take only months, others need several years. They can cost from as little as £40,000 to over £1 million, and may involve synthesising existing evidence, undertaking a trial, or other research collecting new data to answer a research problem.

The final reports from HTA projects are peer reviewed by a number of independent expert referees before publication in the widely read journal series *Health Technology Assessment*.

### Criteria for inclusion in the HTA journal series

Reports are published in the HTA journal series if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

Reviews in *Health Technology Assessment* are termed ‘systematic’ when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.